Methyl morpholine oxide → n-Cyclobutyl-5-(2,6-dichloro-4-formyl-phenoxy)-2-hydroxy-n-methyl-benzamide
反応式
Br[CH2:2][C:3]1[CH:24]=[C:23]([Cl:25])[C:6]([O:7][C:8]2[CH:9]=[CH:10][C:11]([OH:22])=[C:12]([CH:21]=2)[C:13]([N:15]([CH:17]2[CH2:20][CH2:19][CH2:18]2)[CH3:16])=[O:14])=[C:5]([Cl:26])[CH:4]=1.C[N+]1([O-])CC[O:31]CC1>C(#N)C>[CH:17]1([N:15]([CH3:16])[C:13](=[O:14])[C:12]2[CH:21]=[C:8]([O:7][C:6]3[C:23]([Cl:25])=[CH:24][C:3]([CH:2]=[O:31])=[CH:4][C:5]=3[Cl:26])[CH:9]=[CH:10][C:11]=2[OH:22])[CH2:20][CH2:19][CH2:18]1参加物
4
実験手順
To a solution of the title compound of Step G (130 mg, 0.28 mmol) in dry acetonitrile (6 ml) at room temperature under nitrogen was added molecular serves (4 Å, 50 mg). After stirring for about 15 minutes at room temperature, N-methylmorpholine N-oxide (66 mg, 0.57 mmol) was added. The resulting mixture was stirred at room temperature for about 18 hours, then filtered through a short pad of silica gel with an acetonitrile wash. The filtrate was concentrated to afford the title compound (88 mg) as an off-white foam which was used in the next step without further purification. MS (APCI−) Calc: 393.1, found: 392.1 (M−1).